You position:
Home
/
/
AACC 2023: Advancing Global Healthcare with Pluslife's Molecular POCT Solution

AACC 2023: Advancing Global Healthcare with Pluslife's Molecular POCT Solution

  • Categories:News & Events
  • Author:PL1_2
  • Origin:
  • Time of issue:2023-07-27 10:32
  • Views:

(Summary description)

AACC 2023: Advancing Global Healthcare with Pluslife's Molecular POCT Solution

(Summary description)

  • Categories:News & Events
  • Author:PL1_2
  • Origin:
  • Time of issue:2023-07-27 10:32
  • Views:
Information

Pluslife is currently showcasing its cutting-edge technology in molecular diagnostics, focusing on point-of-care testing (POCT) at AACC 2023. Visitors can find Pluslife at Booth No. 817 and explore its latest molecular POCT devices, including Dock Pro 8, Mini Dock and a comprehensive test panel.

 

 

Pluslife molecular POCT solution is developed to expand the border of nucleic acid testing applications from traditional secondary/tertiary care to primary care. With self-patented RHAM technology, internal-produced enzyme raw materials, and automatic production lines for analyzers and tests kits, Pluslife brings affordable, fast, and robust molecular POCT to the market, outperforming similar products in terms of cost and the capabilities to be industrialized in low-and middle-income countries. To date, Pluslife had formed collaborations and product testing with renowned NGOs, such as WHO, FIND, PATH, and BMGF.

 

 

 

Many visitors were attracted by the Pluslife Dock Pro 8. As the latest developed eight-channel molecular POC analyzer, Pluslife Dock Pro 8 is compatible with 16+ different tests with 8 test channels working independently, enabling each patient’s healthcare experience that runs from testing to treatment delivery in 1 hour. Featured with highly integrated functions, such as barcode reader and result printing, Pluslife Dock Pro 8 is well-suited for community-based hospitals, clinics, and testing centers. 

 

 

Apart from Pluslife Dock Pro 8, Pluslife molecular POCT solutions also provide support to quickly obtaining the results of veterinary examination. Pluslife Mini Dock PM003 is a rapid molecular diagnostic system that can be used to detect four canine pathogens or three feline pathogens in a single test with comparable sensitivity and specificity to qPCR tests. The palm-sized portable device empowers community-based vet clinics to offer immediate and actionable test results for pets and animals.

 

 

Currently, Pluslife is making significant strides in the North American market by introducing a diverse range of products. The company is excited to once again participate in AACC 2023 and present extensive diagnostic products to the realm of molecular diagnosis. The next upcoming exhibition of Pluslife will be the Medi-Pharm Expo from Aug 3 to 5 in Ho Chi Minh City, Vietnam.

Tel: +86-20-31703986
E-mail:

market@pluslife.com

  (Business Enquiry)

service@pluslife.com

  (After-Sales&Technical Support)

Add: 3F-Block E, Runhui Science & Technology Park, No. 18 Shenzhou RD, Huangpu District, Guangzhou, Guangdong, China

PLUSLIFE BIOTECH

Monday - Friday, 08:00 -20:00

Copyright © 2021 Guangzhou Pluslife Biotech Co., Ltd.  粤ICP备19038432号  Powered by www.300.cn